Healthcare

SINGAPORE (Jan 7): Dealmaking in the global healthcare sector is forecast to rise modestly this year after 2019 “started with a bang” with news of US pharmaceutical giant Bristol-Myers Squibb’s intended acquisition of Celgene for US$74 billion ($100

SINGAPORE (Jan 2): Raffles Medical Group (RMG) says its 700-bed hospital in Chongqing is now open, with a second hospital to open in Shanghai, Pudong Qintan, this year.

SINGAPORE (Dec 13): OCBC Investment Research is maintaining its “hold” call on First REIT with a lower fair value of $1.05 from $1.34 previously, after factoring in various risks pertaining to the REIT’s master leases and portfolio balancing.  

SINGAPORE (Nov 19): Phillip Capital and CGS-CIMB Research are maintaining their “buy” and “add” calls on Healthcare Management International (HMI) with the respective target prices of 77 cents and 73 cents.

SINGAPORE (Nov 12): Clearbridge Health recorded a loss of $2.5 million for the 3Q ended Sept, 21.4% smaller than its net loss of $3.2 million a year ago on higher revenue derived from its newly-commenced businesses.

SINGAPORE (Sept 21): Cennerv Pharmaceuticals on Wednesday lodged its preliminary prospectus ahead of its planned initial public offering (IPO) on the SGX Catalist board.

SINGAPORE (Sept 21): Singapore, grappling with an aging population and a shortage of high-tech workers, says it needs to bring in foreign talent in areas including software programming while the country rebalances its education system to meet future deman

SINGAPORE/JAKARTA (Sept 19): Southeast Asia’s billionaire Riady family is reshuffling its health-care holdings as its core property business grapples with the emerging-market rout.

SINGAPORE (Aug 28): Health Management International (HMI) reported earnings of RM15.2 million ($5.1 million) for the 4Q ended June, up 43% y-o-y from RM10.7 million a year ago on higher revenue and improved margins.

SINGAPORE (Aug 23): Clearbridge Health’s wholly-owned subsidiary, SAM Laboratory, is acquiring a controlling stake in PT Indo Genesis Medika, a company incorporated in Indonesia, for an aggregate consideration of about IDR 40.7 billion ($3.8 million).